Imatinib, a tyrosine kinase inhibitor that targets CD117 (also known as c-kit), has been shown to inhibit cell growth in vitro, as well as working synergistically with cisplatin to inhibit tumour growth in mouse xenografts [34]. The gene discussed is KIT; the disease is neoplasm.